182 related articles for article (PubMed ID: 37762644)
61. [Prognostic significance of the NPM-ALK fusion gene in bone marrow and peripheral blood for patients with anaplastic large cell lymphoma].
Yang J; Zhao XX; Jin L; Duan YL; Huang S; Zhang M; Zhang R; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):700-3. PubMed ID: 23978023
[TBL] [Abstract][Full Text] [Related]
62. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
[TBL] [Abstract][Full Text] [Related]
63. Detection of the NPM-ALK genomic rearrangement of Ki-1 lymphoma and isolation of the involved NPM and ALK introns.
Ladanyi M; Cavalchire G
Diagn Mol Pathol; 1996 Sep; 5(3):154-8. PubMed ID: 8866227
[TBL] [Abstract][Full Text] [Related]
64. Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.
Bonvini P; Dalla Rosa H; Vignes N; Rosolen A
Cancer Res; 2004 May; 64(9):3256-64. PubMed ID: 15126367
[TBL] [Abstract][Full Text] [Related]
65. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
66. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
Ambrogio C; Martinengo C; Voena C; Tondat F; Riera L; di Celle PF; Inghirami G; Chiarle R
Cancer Res; 2009 Nov; 69(22):8611-9. PubMed ID: 19887607
[TBL] [Abstract][Full Text] [Related]
67. Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma.
Liang X; Branchford B; Greffe B; McGavran L; Carstens B; Meltesen L; Albano EA; Quinones R; Cook B; Graham DK
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e209-13. PubMed ID: 23619105
[TBL] [Abstract][Full Text] [Related]
68. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.
Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D
Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382
[TBL] [Abstract][Full Text] [Related]
69. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
70. Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products.
Luthra R; Pugh WC; Waasdorp M; Morris W; Cabanillas F; Chan PK; Sarris AH
Hematopathol Mol Hematol; 1998; 11(3-4):173-83. PubMed ID: 9844824
[TBL] [Abstract][Full Text] [Related]
71. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma.
Ladanyi M
Cancer Surv; 1997; 30():59-75. PubMed ID: 9547986
[TBL] [Abstract][Full Text] [Related]
72. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
73. SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.
Vishwamitra D; Curry CV; Shi P; Alkan S; Amin HM
Neoplasia; 2015 Sep; 17(9):742-754. PubMed ID: 26476082
[TBL] [Abstract][Full Text] [Related]
74. NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
Murga-Zamalloa CA; Mendoza-Reinoso V; Sahasrabuddhe AA; Rolland D; Hwang SR; McDonnell SR; Sciallis AP; Wilcox RA; Bashur V; Elenitoba-Johnson K; Lim MS
Oncogene; 2017 Apr; 36(15):2085-2094. PubMed ID: 27694894
[TBL] [Abstract][Full Text] [Related]
75. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Anand M; Lai R; Gelebart P
Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
[TBL] [Abstract][Full Text] [Related]
76. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
Kalinova M; Krskova L; Brizova H; Kabickova E; Kepak T; Kodet R
Leuk Res; 2008 Jan; 32(1):25-32. PubMed ID: 17320171
[TBL] [Abstract][Full Text] [Related]
77. A novel model of alternative NF-κB pathway activation in anaplastic large cell lymphoma.
Wang H; Wei W; Zhang JP; Song Z; Li Y; Xiao W; Liu Y; Zeng MS; Petrus MN; Thomas CJ; Kadin ME; Nakagawa M; Waldmann TA; Yang Y
Leukemia; 2021 Jul; 35(7):1976-1989. PubMed ID: 33184494
[TBL] [Abstract][Full Text] [Related]
78. Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues.
Gengenbacher A; Müller-Rudorf A; Poggio T; Gräßel L; Dumit VI; Kreutmair S; Lippert LJ; Duyster J; Illert AL
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434245
[TBL] [Abstract][Full Text] [Related]
79. KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.
Hwang J; Song I; Lee K; Kim HR; Hong EH; Hwang JS; Ahn SH; Lee J
Invest New Drugs; 2020 Oct; 38(5):1282-1291. PubMed ID: 31956933
[TBL] [Abstract][Full Text] [Related]
80. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.
Tsuyama N; Sakamoto K; Sakata S; Dobashi A; Takeuchi K
J Clin Exp Hematop; 2017; 57(3):120-142. PubMed ID: 29279550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
